On a pivotal Thursday, the Supreme Court issued a ruling that allowed telehealth access to the abortion drug mifepristone to continue, a decision that left Justices Clarence Thomas and Samuel Alito in dissent. Their objections signal a potential flashpoint in the ongoing battle over abortion rights, particularly in the wake of the 2022 Dobbs v. Jackson decision, which dismantled the nationwide right to abortion.
Justice Alito characterized the ruling as a “scheme” designed to circumvent the implications of Dobbs, lamenting that the availability of telehealth services has contributed to an increase in abortions. In stark contrast to the past, where traveling out of state for abortion services was common, data from 2025 indicates that more residents in states with total abortion bans have accessed medication abortions via telehealth than sought care elsewhere. Notably, medication abortions accounted for approximately two-thirds of all abortions in the U.S. in 2023, underscoring the critical role of telehealth in reproductive healthcare.
Claire Teylouni, interim co-executive director of Reproductive Equity Now, expressed cautious optimism, stating, “We’re breathing a sigh of relief. I would say that the immediate threat to mifepristone is over.” However, she emphasized that the dissenting opinions from Thomas and Alito reveal an ongoing and significant threat to abortion access.
In his dissent, Thomas invoked the Comstock Act, an antiquated anti-obscenity law from 1873, to argue that mailing abortion medication should be prohibited. He contended that the law bans the use of mail for any drug intended to induce abortion. This perspective, however, is challenged by legal scholars who argue that the Comstock Act is both unenforceable and unconstitutional, particularly in light of First Amendment protections and modern legal precedents.
A 2022 memo from the Department of Justice clarified that the Comstock Act does not prevent the mailing of drugs that could be used for abortions, as there is insufficient evidence to suggest that the sender intends for them to be used unlawfully. Despite this, Thomas and Alito’s dissent reflects a broader conservative strategy to leverage the Comstock Act to pursue a national abortion ban.
Teylouni warned of the potential ramifications of enforcing the Comstock Act, which could disrupt the entire reproductive healthcare supply chain, including access to surgical tools and abortion medications in states where such services are legal. Republican lawmakers have echoed calls for the enforcement of the Comstock Act, aiming to prosecute individuals who obtain mifepristone through the mail.
The political landscape surrounding abortion access remains fraught with uncertainty. In late 2025, the Food and Drug Administration (FDA) initiated a safety review of mifepristone, despite extensive evidence supporting its safety over two decades. Anna Bernstein, a principal federal policy adviser at the Guttmacher Institute, expressed concern over the potential politicization of this review, especially following the resignation of FDA Commissioner Marty Makary and the appointment of Kyle Diamantas, who has reportedly assured anti-abortion advocates of his commitment to reviewing mifepristone as a “top priority.”
The safety profile of mifepristone is well-documented; when used in conjunction with misoprostol, the risk of serious adverse events is less than 1%. In contrast, the risk of maternal death associated with childbirth is approximately 14 times higher than that associated with abortion care. Yet, the political climate continues to cast a shadow over this medical evidence, raising alarms among advocates.
The recent Supreme Court ruling allows providers to continue mailing mifepristone while the case unfolds in lower courts. This decision comes after the 5th U.S. Circuit Court of Appeals had reinstated previous FDA requirements mandating in-person dispensing of mifepristone, which would have severely restricted telehealth access—a vital resource for individuals in states with stringent abortion laws.
Despite this temporary reprieve, advocates remain vigilant. Bernstein noted that the Trump administration appears to be strategically delaying any moves to restrict abortion access until after the midterm elections, aware of the political backlash that could ensue. “We know that the Trump administration understands that it’s politically unfavorable to restrict access to abortion and to mifepristone,” she stated.
While the Comstock Act poses a significant threat, advocates highlight that if mifepristone is no longer available through the mail, individuals can still access medication abortion care using misoprostol alone. However, this method can lead to a more prolonged and uncomfortable experience, as Dr. Ushma Upadhyay from the University of California, San Francisco, explained, noting that patients often report increased side effects.
In the wake of the Supreme Court’s ruling, Teylouni cautioned against complacency, asserting that the decision could have marked a significant setback for abortion access. “Anti-abortion extremists are not going to stop attempting to ban abortion,” she warned, emphasizing the ongoing need for vigilance
Reviewed by: News Desk
Edited with AI assistance + Human research
